

APPLICATIONS

Impurity Analysis of a 22mer DNA Phosphorothioate

Dani Xing, Brian Rivera
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501, USA

Overview

Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterization of oligos, specifically by ion-pair reversed phase liquid chromatography (IP-RPLC), can be quite challenging. Oligos are manufactured by solid phase synthesis, where nucleotides are added in a step-wise manner. As such, impurities such as n-1 and n+1 must be characterized, and this may require extensive method development to optimize. Further, it may be necessary for characterization and quantitation of other closely related impurities related to sample degradation.

Phosphorothioate oligos represent unique challenges. These oligos are characterized by the replacement of one or multiple phosphates in the phosphodiester bond with a sulfur group. Although this results in both increases in stability (i.e. nuclease resistance) and efficacy for the oligo, analytically it makes the separation and characterization more difficult. The thioate modification introduces a stereoisomer, which differs slightly in physicochemical properties and typically leads to peak broadening by standard IP-RPLC methods. Further, characterization and quantitation of an oxidized thioate group is often desired, and this separation can be highly sequence dependent. This is in addition to the standard impurity analysis of n-1, n-2 separation that is necessary for any synthetic oligonucleotide manufactured by solid phase synthesis. Here we highlight the separation of a 22mer DNA phosphorothioate to illustrate the importance of chromatographic separation for proper MS characterization. Notably, we show the separation of n-1 and so-called PS/PO oxidized variant.

Figure 1 shows the separation of the 22mer thioate. The UV chromatogram shows two earlier eluting impurities, labeled as peaks 1 and 2 in the inset. **Figure 2** highlights the full-scan TOF-MS data for the main peak, as well as deconvoluted spectrum. With thioates, these earlier eluting impurities are typically n-1 or n-2 failure sequences, However, these can also be the oxidized "PO" variant.

The deconvoluted spectrum for impurity 1 (**Figure 3a**) predominantly represents the oxidized PO variant. There is some spectral overlap with a presumed n-1 impurity due to a co-elution of the two peaks. **Figure 3b** reveals both n-1 and n-2 impurities. The deconvoluted mass indicates a delta mass of ~329 Da when compared to main peak, likely representing the target sequence minus a guanosine residue. Further characterization of the other earlier impurity peaks failed to yield sufficient spectral quality for deconvolution, though these are likely other short mer impurities.

Here we have demonstrated the capabilities of separating closely eluting impurities of a DNA thioate on the bioZen™ 2.6 µm Oligo column. PS/PO and n-1 impurities were identified. Although LC optimization could further improve the separation of impurities, this method shows proof of concept in characterization, while also highlighting the importance for chromatographic performance in impurity analysis of phosphorothioate oligos.

LC Conditions

- Column:** bioZen 2.6 µm Oligo
- Dimension:** 150 x 2.1 mm
- Part No.:** [00F-4790-AN](#)
- Mobile Phase:** A: 100 mM HFIP and 4 mM TEA in Water
B: 100 mM HFIP and 4 mM TEA in Methanol
- Gradient:** 5-30 % B, 14 minutes
- Flow Rate:** 0.3 mL/min
- Injection:** 1 µL
- Temperature:** 60°C
- Detection:** UV @ 260 nm (Figure 1)
TOF-MS (Figures 2 and 3)
- Sample:** 22mer DNA Phosphorothioate

Figure 1. Impurity Profile of DNA Phosphorothiaote




Figure 2. Full Scan, Deconvoluted Spectrum, Main Peak





Figure 3. Deconvoluted Spectra, Impurity Peaks



APPLICATIONS

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/ChatNow.

Australia

t: +61 (0)2-9428-6444
auiinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 (12) 881 0121
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944
sginfo@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

🌐 All other countries/regions

Corporate Office USA
t: +1 (310) 212-0555
info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

bioZen is a trademark of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2020 Phenomenex, Inc. All rights reserved.